These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 28115678

  • 1. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK, Dash AP.
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [Abstract] [Full Text] [Related]

  • 2. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D.
    Infect Dis Poverty; 2018 Aug 13; 7(1):80. PubMed ID: 30099967
    [Abstract] [Full Text] [Related]

  • 3. Insecticide resistance in phlebotomine sandflies in Southeast Asia with emphasis on the Indian subcontinent.
    Dhiman RC, Yadav RS.
    Infect Dis Poverty; 2016 Nov 07; 5(1):106. PubMed ID: 27817749
    [Abstract] [Full Text] [Related]

  • 4. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.
    Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G.
    Trop Med Int Health; 2008 Jan 07; 13(1):2-5. PubMed ID: 18290995
    [No Abstract] [Full Text] [Related]

  • 5. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U, Joshi R, Agrawal A, Shah V.
    Expert Rev Anti Infect Ther; 2014 Aug 07; 12(8):929-35. PubMed ID: 24930676
    [Abstract] [Full Text] [Related]

  • 6. Implication of vector characteristics of Phlebotomus argentipes in the kala-azar elimination programme in the Indian sub-continent.
    Chowdhury R, Kumar V, Mondal D, Das ML, Das P, Dash AP, Kroeger A.
    Pathog Glob Health; 2016 May 07; 110(3):87-96. PubMed ID: 27376500
    [Abstract] [Full Text] [Related]

  • 7. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.
    J Assoc Physicians India; 2003 Jul 07; 51():686-90. PubMed ID: 14621038
    [Abstract] [Full Text] [Related]

  • 8. Can visceral leishmaniasis be eliminated from Asia?
    Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A.
    J Vector Borne Dis; 2008 Jun 07; 45(2):105-11. PubMed ID: 18592839
    [Abstract] [Full Text] [Related]

  • 9. The Elimination Status of Visceral Leishmaniasis in Southeast Asia Region.
    Rahim S, Karim MM.
    Acta Parasitol; 2024 Sep 07; 69(3):1704-1716. PubMed ID: 39162927
    [Abstract] [Full Text] [Related]

  • 10. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J.
    PLoS Negl Trop Dis; 2017 Nov 07; 11(11):e0005877. PubMed ID: 29145397
    [Abstract] [Full Text] [Related]

  • 11. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
    Pandey K, Pal B, Siddiqui NA, Lal CS, Ali V, Bimal S, Kumar A, Verma N, Das VNR, Singh SK, Topno RK, Das P.
    Indian J Dermatol Venereol Leprol; 2021 Nov 07; 87(1):34-41. PubMed ID: 33580944
    [Abstract] [Full Text] [Related]

  • 12. Recent advances in the diagnosis and treatment of kala-azar.
    Sundar S, Chakravarty J.
    Natl Med J India; 2012 Nov 07; 25(2):85-9. PubMed ID: 22686715
    [Abstract] [Full Text] [Related]

  • 13. Feasibility of a combined camp approach for vector control together with active case detection of visceral leishmaniasis, post kala-azar dermal leishmaniasis, tuberculosis, leprosy and malaria in Bangladesh, India and Nepal: an exploratory study.
    Banjara MR, Kroeger A, Huda MM, Kumar V, Gurung CK, Das ML, Rijal S, Das P, Mondal D.
    Trans R Soc Trop Med Hyg; 2015 Jun 07; 109(6):408-15. PubMed ID: 25918216
    [Abstract] [Full Text] [Related]

  • 14. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.
    Trop Med Int Health; 2012 Nov 07; 17(11):1345-8. PubMed ID: 22882665
    [Abstract] [Full Text] [Related]

  • 15. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S, Chaudhuri SJ, Sardar B, Ghosh M, Saha B, Das NK, Chatterjee M.
    Clin Infect Dis; 2018 Jan 18; 66(3):404-410. PubMed ID: 29020350
    [Abstract] [Full Text] [Related]

  • 16. Active case detection in national visceral leishmaniasis elimination programs in Bangladesh, India, and Nepal: feasibility, performance and costs.
    Huda MM, Hirve S, Siddiqui NA, Malaviya P, Banjara MR, Das P, Kansal S, Gurung CK, Naznin E, Rijal S, Arana B, Kroeger A, Mondal D.
    BMC Public Health; 2012 Nov 20; 12():1001. PubMed ID: 23164318
    [Abstract] [Full Text] [Related]

  • 17. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.
    mBio; 2013 Oct 08; 4(5):e00611-13. PubMed ID: 24105765
    [Abstract] [Full Text] [Related]

  • 18. Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.
    Garlapati R, Iniguez E, Serafim TD, Mishra PK, Rooj B, Sinha B, Valenzuela JG, Srikantiah S, Bern C, Kamhawi S.
    Front Cell Infect Microbiol; 2021 Oct 08; 11():641632. PubMed ID: 33768013
    [Abstract] [Full Text] [Related]

  • 19. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
    Salam MA, Siddiqui MA, Nabi SG, Bhaskar KR, Mondal D.
    J Health Popul Nutr; 2013 Jun 08; 31(2):294-7. PubMed ID: 23930349
    [Abstract] [Full Text] [Related]

  • 20. How do health care providers deal with kala-azar in the Indian subcontinent?
    Kumar N, Singh SP, Mondal D, Joshi A, Das P, Sundar S, Kroeger A, Hirve S, Siddiqui NA, Boelaert M.
    Indian J Med Res; 2011 Sep 08; 134(3):349-55. PubMed ID: 21985818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.